Abstracts and Publications
Initial results from dose escalation of a phase 1/2, first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors
Vasselli J, De Souza P, Frentzas S, et al.
Poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2022
Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors
Vasselli J, De Souza P, Frentzas S, et al.
Poster presentation at the American Society of Clinical Oncology (ASCO), June 2022
AU-007, a computationally designed human antibody to the CD25-interacting domain of IL-2, demonstrates strong activity in murine syngeneic tumors in combination with IL-2 and PD-1 or PD-L1 antibodies
Amit I, Levin I, Wyant T, et al.
Preclinical poster, March 2022
AU-007, a computationally designed human antibody, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 negative feedback loop and preventing Treg expansion
Amit I, Levin I, Wyant T, et al.
Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2021
Computationally Designed Antibodies Unlocking the Body’s Own IL-2 to Fight Cancer
Yanay Ofran, Ph.D.
Poster presentation video at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2021